Neal F. Fowler serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 2010 and as a member of the compensation and governance/nominating committees. Mr. Fowler is Chief Executive Officer of Liquidia Technologies, Inc., and led the efforts to create two spin-out companies from Liquidia, Envisia Therapeutics and Lq3 Pharmaceuticals. Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company’s legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, holding a variety of management positions of increasing responsibility.
Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill.